Washington, D.C.

In the Matter of

Inv. No. 337-TA-489
_______________________________________ )

AGENCY: U.S. International Trade Commission.
SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not toreview an initial determination (“ID”)(Order No. 19) issued by the presiding administrative law judge(“ALJ”) finding a violation of section 337 and that the domestic industry requirement has been met in theabove-captioned investigation. FOR FURTHER INFORMATION CONTACT: Wayne Herrington, Esq., Office of the General Counsel,U.S. International Trade Commission, 500 E Street, S.W., Washington, D.C. 20436, telephone 202-205-3090. Copies of all nonconfidential documents filed in connection with this investigation are or will beavailable for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of theSecretary, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone202-205-2000. General information concerning the Commission may also be obtained by accessing itsInternet server (http://www.usitc.gov). The public record for this investigation may be viewed on theCommission’s electronic docket (EDIS) at http://edis.usitc.gov. Hearing-impaired persons are advisedthat information on the matter can be obtained by contacting the Commission's TDD terminal on 202-205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on March 6, 2003,based on a complaint filed by Pfizer, Inc. (“Pfizer”) of New York, New York. 68 Fed. Reg. 10749(March 6, 2003). The complaint, as supplemented, alleged violations of section 337 of the Tariff Act of1930 in the importation into the United States, sale for importation, and sale within the United States afterimportation of certain sildenafil or any pharmaceutically acceptable salt thereof, including sildenafil citrate, and products containing same by reason of infringement of claims 1-5 of Pfizer’s U.S. Patent No.
5,250,534 (“the ‘534 patent”).
Fifteen respondents were named in the Commission’s notice of investigation. Of these, eleven were found to be in default. Two other respondents were never found to have been served with thecomplaint and notice of investigation, and have not otherwise participated in the investigation. Anotherrespondent has been terminated from the investigation on the basis of a settlement agreement. Onerespondent is the subject of a motion to terminate the investigation on the basis of a consent order, whichthe ALJ has granted and which is currently before the Commission.
On October 6, 2003, Pfizer filed a motion pursuant to Commission rule 210.18 (19 C.F.R. § 210.18) for summary determination on the issues of the existence of a domestic industry and violation ofsection 337. Pfizer’s motion sought a general exclusion order and a cease and desist order againstrespondent #1 Aabaaca Viagra LLC (“Aabaaca”). On October 16, 2003, the Commission investigativeattorney filed a response in support of Pfizer’s motion. No other responses to the motion were filed.
On October 27, 2003, the ALJ issued the subject ID finding that Pfizer has demonstrated that there is a violation of section 337 by reason of the defaulting respondents’ importation and sale ofsildenafil, sildenafil salts, or sildenafil products that infringe one or more of claims 1-5 of the ‘534 patent. He also found the domestic industry requirement satisfied. As to remedy, the ALJ found that the legalframework for considering whether to issue a general exclusion order in the circumstances of this case issection 337(g)(2), not section 337(d)(2). He recommended the issuance of a general exclusion order, butdid not recommend the issuance of a cease and desist order against respondent Aabaaca. He alsorecommended that the bond permitting temporary importation during the Presidential review period be setat 100 percent of entered value. No party petitioned for review of the ID.
In connection with the final disposition of this investigation, the Commission may (1) issue an order that could result in the exclusion of the subject articles from entry into the United States, and/orissue one or more cease and desist orders that could result in respondents being required to cease anddesist from engaging in unfair acts in the importation and sale of such articles. Accordingly, theCommission is interested in receiving written submissions that address the form of remedy, if any, thatshould be ordered. If a party seeks exclusion of an article from entry into the United States for purposesother than entry for consumption, it should so indicate and provide information establishing that activitiesinvolving other types of entry either are adversely affecting it or likely to do so. For background, see Inthe Matter of Certain Devices for Connecting Computers via Telephone Lines, Inv. No. 337-TA-360,USITC Pub. No. 2843 (December 1994) (Commission Opinion). The Commission considers the questionof remedy to include the ALJ’s finding that the legal framework for considering whether to issue ageneral exclusion order in the circumstances of this case is section 337(g)(2), not section 337(d)(2).
If the Commission contemplates some form of remedy, it must consider the effects of that remedy upon the public interest. The factors the Commission will consider in this investigation include theeffect that a remedial order would have on (1) the public health and welfare, (2) competitive conditions inthe U.S. economy, (3) U.S. production of articles that are like or directly competitive with those that aresubject to investigation, and (4) U.S. consumers. The Commission is therefore interested in receivingwritten submissions that address the aforementioned public interest factors in the context of thisinvestigation.
If the Commission orders some form of remedy, the President has 60 days to approve or disapprove the Commission’s action. During this period, the subject articles would be entitled to enter theUnited States under bond, in an amount determined by the Commission and prescribed by the Secretary ofthe Treasury. The Commission is therefore interested in receiving submissions concerning the amount ofthe bond that should be imposed. WRITTEN SUBMISSIONS: The parties to the investigation, interested government agencies, and anyother interested parties are encouraged to file written submissions on remedy, the public interest, andbonding. Such submissions should address the October 27, 2003, recommended determination by the ALJon remedy and bonding. Complainant and the Commission investigative attorney are also requested tosubmit proposed orders for the Commission’s consideration. The written submissions and proposed orders must be filed no later than close of business on December 12, 2003. Reply submissions, if any,must be filed no later than the close of business on December 19, 2003. No further submissions on theseissues will be permitted unless otherwise ordered by the Commission.
Persons filing written submissions must file with the Office of the Secretary the original document and 14 true copies thereof on or before the deadlines stated above. Any person desiring to submit adocument (or portion thereof) to the Commission in confidence must request confidential treatment unlessthe information has already been granted such treatment during the proceedings. All such requests shouldbe directed to the Secretary of the Commission and must include a full statement of the reasons why theCommission should grant such treatment. See section 201.6 of the Commission’s Rules of Practice andProcedure, 19 C.F.R. § 201.6. Documents for which confidential treatment by the Commission is soughtwill be treated accordingly. All nonconfidential written submissions will be available for public inspectionat the Office of the Secretary.
This action is taken under the authority of section 337 of the Tariff Act of 1930, 19 U.S.C. § 1337, and section 210.42 of the Commission’s Rules of Practice and Procedure, 19 C.F.R. § 210.42.

Source: http://65-121-221-210.dia.static.qwest.net/secretary/fed_reg_notices/337/337_489_notice11242003.PDF

Jason carroll_cv

CURRICULUM VITAE Office Address: Cancer Research UK/Cambridge Research Institute Place of Birth: Date of birth: Education: B.Sc. (Molecular Biology) University of Melbourne (1st Class Honours), Melbourne, Australia Ph.D. (Cancer Research) The Garvan Institute and University of New South Wales, Sydney, Australia Professional Experience: Research Assistant, Genomi

Obsessive compusive disorder in young people

How is Obsessive Compulsive Disorder Treated? 1. Behavioral Treatment for Compulsions: Never discontinue these medications abruptly and Obsessive One of the most effective psychological treatments is always consult a physician prior to decreasing them. exposure plus response prevention (ERP). Very 3. Rebuilding Confidence Compulsive basically, ERP involves exposure to t

Copyright © 2010-2019 Pdf Physician Treatment